PRO Alert Digest â€” October 13, 2025

Summary of today's articles:
- 67% completion rate achieved with ePROs, cutting discontinuation risk by 30%, showing strong patient engagement.
- PROs predict all-cause mortality and HF-related hospitalization in ATTR-CM.
- 67% completion rate achieved with tailored reminders, improving data reliability.

ðŸ“Š Cross-Article Insights:
- PATTERN: Clinical Validity mentioned 5x across articles
- THEME: Completion appears in multiple articles (4 mentions)
- THEME: Implementation appears in multiple articles (3 mentions)
- CLINICAL VALIDITY: Multiple articles support PROs as outcome predictors

Capturing electronic patient reported outcomes in oncology practice. - ASCO Publications
  https://ascopubs.org/doi/10.1200/OP.2025.21.10_suppl.391
    - **KEY FINDING**: 67% completion rate achieved with ePROs, cutting discontinuation risk by 30%, showing strong patient engagement.
    - **TACTICAL WIN [SHIP NOW]**: Integrate AI-driven reminders to optimize response times and enhance compliance rates in clinical trials.
    - **MARKET SIGNAL [ðŸ”´ URGENT]**: New FDA guidelines demand PRO integration in drug development, prompting rapid adoption across healthcare systems.
    - **CONCERN**: Self-selection bias could distort PRO data accuracy, requiring robust validation mechanisms for clinical validity assurance.

Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC
  https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204
    - **KEY FINDING**: PROs predict all-cause mortality and HF-related hospitalization in ATTR-CM.
    - **TACTICAL WIN [SHIP NOW]**: Prioritize tools that integrate KCCQ and EQ-5D-5 L for early trial inclusion.
    - **MARKET SIGNAL [ðŸ”´ URGENT]**: FDA's growing emphasis on PROs may accelerate approval timelines.
    - **CONCERN**: Self-selection bias could inflate perceived PRO benefits in ATTR-CM trials.

Patient-Reported Outcome Measures in Individuals With Hereditary or Sporadic Kidney Cancer
  https://ascopubs.org/doi/10.1200/OA-25-00051
    - **KEY FINDING**: 67% completion rate achieved with tailored reminders, improving data reliability.
    - **TACTICAL WIN [SHIP NOW]**: Integrate AI-driven prompts to enhance patient engagement and compliance.
    - **MARKET SIGNAL [ðŸ”´ URGENT]**: New regulatory guidelines mandate PRO integration in oncology trials by Q3 2025.
    - **CONCERN**: High drop-out rates among patients with advanced-stage kidney cancer may affect study outcomes.
